Presideo, Verisign partner, gain Medquist as customer
Presideo, Verisign partner, gain Medquist as customerPresideo, a firm specializing in digital identity management in healthcare, and Verisign, a firm concentrating on security infrastructure for e-business, have partnered to provide services to
Presideo, Verisign partner, gain Medquist as customer
Presideo, a firm specializing in digital identity management in healthcare, and Verisign, a firm concentrating on security infrastructure for e-business, have partnered to provide services to the healthcare industry. Verisign will combine its 24/7 managed trust services infrastructure with Presideos identity management products to develop online physician credentialing; biometric authentication; interoperability services; and a policy, legal, and business framework specific to healthcare. Presideo and Verisign will jointly market these security services.
The firms have already sold Medquist, a transcription services vendor owned by Philips, on their joint offering. Medquist will embed Internet security infrastructure and digital certificates into existing products and Medquist.net products.
- Search Again
- Return To HNN Homepage
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
